Healthcare Industry in India: Investment & Growth Opportunities

India’s healthcare sector is entering a new phase of formalisation, consolidation and capital-driven growth. The market is estimated at US$400–420 billion in 2025, while healthcare expenditure remains relatively under-penetrated at 3.58% of GDP versus a global average of 6.74%. At the same time, out-of-pocket expenditure has declined from 64.2% to 43.4% over the past decade, indicating a gradual shift toward organised and financed healthcare.

Where Is the Opportunity in the Healthcare Industry in India?

The opportunity is not limited to hospitals. The report identifies hospitals, diagnostics, pharmaceuticals, medical devices, health insurance, retail pharmacy, biotechnology and digital health as major segments with different growth and investment characteristics.

Hospital delivery alone is projected to grow from US$193.4 billion in 2025 to US$364.6 billion by 2034, representing a 7.3% CAGR. Healthcare IPO activity is also deepening, with 11 healthcare IPOs raising ₹12,317 crore during 2025 through August 2026, including Manipal Health Enterprises’ ₹9,275 crore issue.

Yet the biggest opportunity may lie in the industry’s fragmentation. Diagnostics and retail pharmacy remain highly fragmented, while hospitals are expanding through specialty formats, hub-and-spoke models and brownfield capacity additions.

Capital Is Becoming More Selective in the Healthcare Industry in India?

Healthcare capital is no longer following a single route. Private equity, venture capital, strategic investors, foreign capital, M&A and public markets are all contributing to the funding ecosystem.

Importantly, scale alone is not enough. The report highlights that margin quality and operating performance increasingly influence how healthcare businesses are valued. Hospitals, for example, command substantially higher valuation multiples than several other healthcare segments.

The Strategic Takeaway

The report’s central message is clear: fragmentation creates opportunity, but capital is becoming more disciplined.

Underserved Tier-2 and Tier-3 markets, specialty healthcare, diagnostics, medical devices, CDMO/CRAMS, preventive healthcare and asset-light models offer different opportunities, but each requires a distinct investment and financing strategy.

For promoters and investors, the question is therefore not simply “How fast is healthcare growing?”

It is:

“Where is sustainable growth, attractive economics and deployable capital converging?”

That distinction can materially influence valuation, fundraising, expansion and M&A decisions.

Download the Full Healthcare Industry Report